Napjainkban a kormányzattól és a biztosítóktól kezdve a szolgáltatókig és a fogyasztókig mindenki az egészségügyi piaci versenyről beszél. De mit is értenek piaci versenyen? Vajon azonos dolgokról beszélnek-e? Mivel az egészségpolitika alakításában az egészségügy...

Increases in Home Care (HC) services for the elderly have been a policy priority in recent decades. HC services include Home Health Care (HHC) and Homemaking/Personal Support (HM). We explored the interrelationship between receipt of publicly funded HM and HHC, and the determinants of the...

This study investigates hospitals' dynamic incentives to select patients when hospitals are remunerated according to a prospective payment system of the DRG type. Given that prices typically reflect past average costs, we use a discrete-time dynamic framework. Patients differ in severity within...

The purpose of this paper is to analyze the multilevel methodology in order to estimate the effect of primary care physician in the pharmaceutical expenditure of the patient. We use individual data from population that is part of the Spanish public health system in the Autonomous Community of...

Background:Background: The National Centre for Pharmacoeconomics, in collaboration with the Health Services Executive, considers the cost effectiveness of all new medicines introduced into Ireland. Health Technology Assessments (HTAs) are conducted in accordance with the existing agreed Irish...

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death and disability worldwide, but before the development of several new pharmacological treatments little could be done for COPD patients. Recognition that these new treatments could significantly improve the...

Background:Background: Specialized community pharmacy services, involving the provision of disease state management and care by pharmacists, have been developed and trialled and have demonstrated very good health outcomes. Most of these services have been developed from a healthcare professional...

The recent rush of enthusiasm for public investment in comparative effectiveness research (CER) in the US has focussed attention on these public investments. However, little attention has been given to how changing public investment in CER may affect private manufacturers' incentives for CER,...